Pharmaceutical

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Non-Hodgkin Lymphoma: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Non-Hodgkin Lymphoma.

Apr 19, 2024 - 00:00
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Non-Hodgkin Lymphoma.
Read the original article

Tags:

Previous Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Small-Cell Lung Cancer: ...

Next Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Melanoma: Likelihood of ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Novo Nordisk invests $4.1bn in manufacturing facility in NC

Novo Nordisk invests $4.1bn in manufacturing facility i...

Jun 26, 2024

Biden directs HHS to boost contraception access, a year after Dobbs decision

Biden directs HHS to boost contraception access, a year...

Jun 24, 2023

Biogen and Neomorph enter molecular glue degrader deal

Biogen and Neomorph enter molecular glue degrader deal

Nov 1, 2024